

Review

Beneficial Effects of Tianeptine on Hippocampus-Dependent Long-Term Memory and Stress-Induced Alterations of Brain Structure and Function

Phillip R. Zoladz¹, Carmen Muñoz² and David M. Diamond^{3,4,5,*}

¹ Department of Psychology & Sociology, Ohio Northern University, Ada, OH 43222 USA

² Servier International, 35 rue de Verdun, 92284 Suresnes, France

³ Research & Development Service, James A. Haley VA Hospital, Tampa, FL 33612, USA

⁴ Department of Psychology, Cognitive and Neural Sciences Division, University of South Florida, Tampa, FL 33612, USA

⁵ Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL 33612, USA

* Author to whom correspondence should be addressed; E-Mail: ddiamond@mail.usf.edu; Tel.: 813-974-0480; Fax: 813-974-4617.

Received: 19 July 2010; in revised form: 26 August 2010 / Accepted: 31 August 2010 /

Published: 11 October 2010

Abstract: Tianeptine is a well-described antidepressant which has been shown to prevent stress from producing deleterious effects on brain structure and function. Preclinical studies have shown that tianeptine blocks stress-induced alterations of neuronal morphology and synaptic plasticity. Moreover, tianeptine prevents stress from impairing learning and memory, and, importantly, demonstrates memory-enhancing properties in the absence of stress. Recent research has indicated that tianeptine works by normalizing glutamatergic neurotransmission, a mechanism of action that may underlie its effectiveness as an antidepressant. These findings emphasize the value in focusing on the mechanisms of action of tianeptine, and specifically, the glutamatergic system, in the development of novel pharmacotherapeutic strategies in the treatment of depression.

Keywords: antidepressant; synaptic plasticity; memory; animal model; glutamate; stress

1. Introduction

Depression is a cause of significant distress and financial burden across the globe [1,2], and continued research assessing its etiology is essential to facilitate the development of better treatments for the disorder. Although considerable progress has been made in describing the physiological and behavioral *sequelae* that result from depression, the factors responsible for its development and maintenance remain largely unknown. A considerable proportion of what we know about the biological basis of this disorder has come about through studies examining pharmacological agents that treat it most effectively. Indeed, the dogmatic view that abnormally low levels of monoamine neurotransmitters result in depression developed out of the incidental finding that efficacious antidepressant agents, such as monoamine oxidase inhibitors and tricyclic antidepressants, substantially increased monoamine neurotransmitter levels [3]. Even today, the most frequently prescribed medications for depression are the selective serotonin reuptake inhibitors (SSRIs), whose primary mechanism of action involves increasing extracellular serotonin levels [4,5].

Recent work has suggested that the widely held view that depression results from abnormally low levels of monoamine neurotransmitters is an oversimplification of a much more complex process, and that elevated monoamine levels provides only an indirect contribution to therapy for depressive symptoms [6–8]. Thus, antidepressant agents with a primary mode of action to increase monoamine neurotransmitter levels, such as the SSRIs, are effective in only a subset of people suffering from depression [9–11]. Moreover, SSRIs are typically used in a polypharmacy (multi-drug) approach to the treatment of depression, which suggests that the focus on the SSRI-based serotonergic component of depression is incomplete. It is therefore evident that mechanisms other than alterations of monoamine neurotransmitter levels are involved in the development and maintenance of depression.

An alternative and well-established treatment for depression is tianeptine, a clinically effective antidepressant whose non-monoaminergic mechanism of action is quite unlike that of other pharmacological treatments for the disorder; tianeptine's antidepressant effects primarily involve the modulation of glutamatergic neurotransmission and the modulation of the capacity for the brain to exhibit synaptic plasticity [9,12–17]. Tianeptine reduces depressive symptoms in individuals with mild to severe forms of the disorder, and unlike SSRI's, tianeptine is effective with fewer side effects in a monotherapy approach [18–22]. Tianeptine's effectiveness in treating depression is of clinical, as well as conceptual, significance. The contrast in mechanistic actions between tianeptine and other types of antidepressants serves as a challenge to the heuristic value of the monoamine hypothesis of the disorder [23,24].

In this review, we have provided an update on research on stress, depression and neuroplasticity, and more specifically, we have described the influence of tianeptine on cognitive and physiological measures of brain function. In addition, we have integrated the literature on stress, memory and synaptic plasticity with our recent work on the enhancement of long-term hippocampus-dependent memory by acute administration of tianeptine. These findings are potentially relevant toward the amelioration of cognitive deficits and hippocampal pathophysiology which are endemic to depression [25–27].

2. Stress, Neuroplasticity and Symptoms of Depression

Two commonalities to almost all mood and anxiety disorders include alterations in neuroplasticity and stress as contributing factors [28–31]. Alterations in neuroplasticity involve structural and functional changes in how the brain processes information. It has been hypothesized that many of the behavioral symptoms of depression are manifested through changes in brain neurochemical levels that ultimately result in structural changes in brain regions that process emotional and cognitive information, including the hippocampus, prefrontal cortex (PFC) and amygdala [16,32,33]. The hippocampus is a medial temporal lobe structure which is important for declarative memory in humans [34,35] and spatial working memory in rodents [36–41]; the PFC is located in the anterior part of the frontal lobe and plays an important role in complex cognitive processes, such as planning, decision-making and behavioral flexibility [42]; and, the amygdala is an almond-shaped structure in the medial temporal lobe which is highly involved in emotion and memory [43–45].

In support of the notion that depression involves alterations of neuroplasticity, studies have reported significant reductions of hippocampal and PFC volumes in depressed patients [46–48]. In addition, depressed individuals exhibit impaired performance on hippocampus- and PFC-dependent cognitive tasks, impairments that have been associated with reduced or abnormal activity in each of these respective brain regions while depressed patients were engaged in such tasks [49,50]. In contrast to the hippocampus and PFC, amygdala volume and activity are increased in depressed individuals, and with successful treatment, significantly decline [51–53]. Thus, depression is clearly associated with significant changes in brain structure and function, which may ultimately explain the expression of depression's behavioral symptoms.

It has been well-established that stress is a significant contributor to one's likelihood of developing depression [54,55]. Thus, a major focus of preclinical researchers has been to define the physiological and behavioral alterations that result from stress and to ascertain how they can be prevented through pharmacological means. Animal models of stress provide unique advantages over studying humans with depression in that they afford researchers a greater amount of control over experimental variables, and they allow the investigators to assess neurobiological endpoints (e.g., neuron structure, cellular and molecular measures) that would be difficult, if not impossible, to assess in human patients. The models are also useful because once they reveal the physiological and behavioral effects that stress exerts on brain structure and function, investigators can use this information to develop novel pharmacological agents in alleviating such effects. Of course, researchers must exert caution when applying the findings from animal models to the human disorder. Animal models are not necessarily capable of modeling all of the core symptoms of depression, and those symptoms that can be modeled do not always reflect the underlying mechanisms involved in the human situation [56]. Thus, animal models do provide researchers with several advantages in developing a better understanding of the neurobiological basis of depression, but the models must be employed and interpreted prudently.

Extensive preclinical research has shown that chronic stress produces physiological and behavioral alterations (e.g., abnormal hypothalamus-pituitary-adrenal (HPA) axis functioning, cellular and molecular abnormalities, anhedonia, learned helplessness, cognitive impairments) which are analogous to those observed in people with depression [57–59]. In terms of neuroplasticity, investigators have found that in animal models of chronic stress there is a significant reduction of the length, spine

density and arborization of dendrites on neurons in the hippocampus [60–67] and PFC [68–73], and increases in each one of these parameters in neurons of the amygdala [66,74]. Correspondingly, these chronic stress regimens have been shown to produce significant impairments of hippocampus-dependent (e.g., spatial learning) [75–81] and PFC-dependent (e.g., attention set-shifting, reversal learning) [68,71] memory, while enhancing performance on amygdala-dependent tasks (e.g., fear conditioning) [60,82]. Moreover, the same chronic stress regimen that results in hypertrophy of amygdala neurons increases the expression of anxiety-like behaviors in rats tested on the elevated plus maze [66,74].

The effects of chronic stress on hippocampal [60,77] and PFC [72] morphology have been found to be reversible – that is, the dendrites of neurons in these brain regions re-grow when the chronic stress regimen is discontinued. On the other hand, the effects of chronic stress on amygdala morphology and the amygdala-mediated expression of anxiety-like behavior do not reverse following the termination of stress [83]. The ability of neurons in the hippocampus and PFC to recover after the termination of stress appears to depend on the age of the subject under investigation; a recent study revealed that young (*i.e.*, 3-month-old) rats exhibited full recovery of neurons in the PFC following cessation of chronic restraint stress, while middle-aged (*i.e.*, 12-month-old) and aged (*i.e.*, 20-month-old) rats exhibited minimal recovery in response to identical stress procedures [84]. This finding is particularly relevant to our understanding of how to develop better treatments for depression because it suggests that as the age of the individual increases, neuroplasticity, and the corresponding ability for neurons to recover following injuries that could be associated with depression, decreases. Therefore, if reversing the alterations of neuroplasticity that are induced by depression is key to successful treatment of the disorder, we must not look to develop pharmacological agents that merely prevent these alterations; rather, we should look to develop pharmacological agents that promote neuron growth and resilience.

Research over the past couple of decades has shown that the effects of chronic stress on the morphology and functionality of the hippocampus, PFC and amygdala are mediated by an interaction between glucocorticoids and *N*-methyl-D-aspartate (NMDA) receptor activity. For instance, chronic administration of corticosterone mimics the effects of chronic stress on hippocampal [77,85,86] and PFC [87] morphology, and the stress-induced dendritic retraction observed in the hippocampus is blocked by steroid synthesis inhibitors [88], as well as NMDA receptor antagonists [88] and agents that significantly reduce extracellular levels of glutamate (e.g., phenytoin) [64,89]. These findings resonate with research in depressed patients, which indicates that these individuals exhibit an overactive HPA axis [90,91] and abnormal brain glutamatergic levels [92–94].

3. Tianeptine Prevents Stress-Induced Alterations of Neuroplasticity

Daily administration of tianeptine has been shown to prevent the chronic stress-induced reduction of overall hippocampal volume [95] and CA3 dendrites [60,96,97], as well as the chronic stress-induced hypertrophy of neurons in the amygdala [16,98]. Additional work has revealed that tianeptine prevents the effects of chronic stress on hippocampus-dependent learning and memory [79,99,100] and the amygdala-mediated enhancement of anxiety-like behavior [16,98]. The latter finding may be relevant to other work reporting that chronic tianeptine treatment reduces the expression of auditory fear conditioning, an amygdala-dependent task [101]. It is notable that the SSRIs fluoxetine and fluvoxamine were ineffective in preventing the effects of chronic stress on CA3 morphology [96], providing compelling evidence that SSRIs and tianeptine act through different cellular and molecular mechanisms.

The hippocampus is one of only two brain regions in the adult mammalian brain that produces new neurons through a process known as neurogenesis [102]. Although the functional role of neurogenesis has remained a highly debated topic, studies have provided evidence linking hippocampal neurogenesis with hippocampus-dependent learning and memory [103,104]. In addition, researchers have hypothesized that the pathogenesis of depression involves impaired hippocampal neurogenesis [105–109]. Accordingly, in animal models, chronic stress significantly reduces hippocampal neurogenesis [110–115] and increases apoptotic cell death in the hippocampus and temporal cortex [111,116,117]. Clinically effective antidepressants, including tianeptine, prevent the effects of chronic stress on hippocampal neurogenesis [95,105,115]. Tianeptine has also been reported to block the chronic stress-induced increase in apoptotic cell death in the temporal cortex [118], which may be related to its prevention of the chronic stress-induced reduction of cerebral metabolites associated with neuronal viability (e.g., *N*-acetyl-aspartate) [95].

Neurotrophic factors are significant regulators of cell survival and proliferation, thus making them vitally important for the process of neurogenesis [119]. Some of the most extensively characterized neurotrophic factors include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4). Numerous studies have shown that acute and chronic stress significantly reduce neurotrophic factor levels [115,120–122], with many of the studies focusing on the stress-induced reduction of BDNF levels in the hippocampus [114,123–131]. This effect has become the center of attention, at least in part, because several studies have reported significantly reduced levels of serum and hippocampal BDNF in depressed patients [132–134]. BDNF knock-out mice have been reported to exhibit morphological changes in the hippocampus that are comparable to those observed following exposure to chronic restraint stress [135]. Interestingly, investigators have shown that the efficacy of antidepressants in ameliorating behavioral symptoms of depression in depressed patients and in animal models of stress depends on their ability to increase BDNF levels [134,136,137].

Tianeptine's prevention of the effects of chronic stress on neurogenesis may involve blocking the stress-induced reduction of neurotrophic factor levels in the hippocampus [123]. Another study found that chronic tianeptine treatment significantly increased BDNF levels in the rat amygdala, independent of whether or not the rats were exposed to stress [135]. According to Reagan and colleagues, the amygdala may be the site of the initiation of chronic stress-induced morphological changes in other brain regions, such as the hippocampus and PFC [135,138]. In support of this hypothesis, clinical studies on depressed patients have reported that morphological changes in the amygdala precede those that are observed in the hippocampus [139]. Therefore, tianeptine's effectiveness as an antidepressant treatment may result from its enhancement of neurotrophin actions in the amygdala.

4. Stress and Synaptic Plasticity: Stabilization by Tianeptine

Synaptic plasticity involves activity-induced changes in synaptic function which then affect how the synapse will subsequently respond to afferent activity. Synaptic plasticity has long been hypothesized to be important for learning and memory, and it has been speculated that people with depression exhibit abnormal synaptic plasticity in the hippocampus, PFC and amygdala [16,17,30]. To indirectly address this issue, investigators have used animal models to examine the effects of stress on long-term potentiation (LTP), a physiological model of learning and memory involving an enhancement of

synaptic efficacy following high-frequency stimulation of afferent fibers [140]. Extensive work has shown that stress impairs the induction of LTP in the hippocampus and PFC, while facilitating its induction in the amygdala [141–144]. This stress-induced modulation of synaptic plasticity has been shown to be mediated by interactions among glucocorticoids [145–147], glutamatergic NMDA receptors [148–150] and amygdala-induced modulation of hippocampal plasticity [151,152].

Tianeptine has been shown to block the stress-induced impairment of LTP in the hippocampus and PFC, without interfering with the stress-induced enhancement of LTP in the basolateral amygdala (BLA) [153–156]. Tianeptine blocked the inhibitory effects of stress on hippocampal LTP and primed burst potentiation (PBP), a low-threshold form of LTP, when it was administered either before or after the stress experience [155,156]. Other antidepressants, including some SSRIs, have also been reported to block the effects of stress on LTP in the hippocampus and PFC, although these effects have been less significant and more transitory in nature [154,157].

5. Tianeptine Protects Memory from Stress and Enhances Learning and Memory

Extensive work has shown that acute stress impairs hippocampus-dependent learning and memory in humans and rodents [141–144,158,159]. We previously reported that tianeptine, but not the anxiolytic propranolol, blocked the predator stress-induced impairment of rat spatial memory in the radial-arm water maze (RAWM) [160]. The RAWM is a water-filled tank with six swim arms radiating from an open central area; a hidden platform is placed at the end of one of the arms, and rats are given several training trials to learn the location of the hidden platform. Tianeptine prevented the effects of stress on memory without altering the stress-induced increase in glucocorticoids, indicating that tianeptine's memory-protective effects can occur without attenuating the stress-induced activation of the HPA axis. This finding was also consistent with *in vivo* electrophysiological studies reporting that tianeptine blocked the effects of stress on hippocampal LTP without affecting stress-induced increases in corticosterone levels in rats [155].


In more recent work, we reported that predator stress impaired spatial memory in rats that were adrenalectomized (ADX) [161]. This finding demonstrates that exposure to a cat can impair memory in the absence of a stress-induced increase in glucocorticoid levels. This finding, alone, provides strong evidence that the acute stress-induced impairment of hippocampus-dependent learning does not require a stress-induced elevation of glucocorticoid levels. More importantly, we found that tianeptine prevented the stress-induced impairment of spatial learning in ADX animals, as well. Collectively, these findings provide convincing evidence that, under stress conditions, tianeptine's memory-protective effects are not accomplished by modulation of glucocorticoid levels.

Studies have also shown that tianeptine administration, under non-stress conditions, increases the magnitude of synaptic plasticity (LTP and PB potentiation) in the hippocampal CA1 region [155,156]. This finding suggests that tianeptine should enhance learning and memory. Indeed, studies have shown that tianeptine enhances spontaneous alternation behavior, as well as performance on discrimination tasks in the T-maze and radial arm maze [162,163]. In contrast, acute administration of the SSRI fluoxetine impaired performance on the radial arm maze discrimination task [162], a finding that is relevant to other work reporting that fluoxetine impairs the induction of LTP in hippocampal slices [155].

We have extended the findings on tianeptine's procognitive effects by assessing its influence on the spatial memory of rats trained in the RAWM. In the experiment, rats (250–275 g; Charles River

Laboratories) were injected intraperitoneally with one of five doses of tianeptine (0.25, 0.50, 1, 5, 10 mg/kg) or vehicle (0.9% saline, 1 mL/kg) and then 30 min later, the rats were given RAWM training, following previously-described methods [78,160,161,164–171]. Briefly, the rats were given 4 trials to learn the location of a hidden escape platform, which was placed at the end of one of six arms, in the RAWM. Arm entry errors (*i.e.*, entries into arms that did not contain the hidden platform) served as an indicator of the rat's accuracy of its memory for the hidden platform location. Following the 4 acquisition trials, the rats spent a 1-hour delay period in their home cages. This delay period terminated with a single short-term memory test trial in the RAWM. Twenty-four hours later, the rats were given a single memory test trial in the RAWM to assess their long-term memory for the hidden platform location. The doses of tianeptine used in this experiment include the same doses that have been shown to enhance hippocampal LTP and PBP [16,17,155,156], and to block the effects of chronic stress on hippocampal morphology [60,95–97] and hippocampus-dependent learning and memory [79,99,100].

Figure 1. Pre-training administration of tianeptine enhanced long-term (24-hours) spatial memory in the RAWM.



The top graph illustrates arm entry errors during the four acquisition trials in the RAWM (1–4; left) and memory test trial performance 1 and 24 hours later. The acquisition data were analyzed with a mixed-model ANOVA, which revealed a significant main effect of trials, $F(3,126) = 25.67$, $p < 0.001$, indicating that the rats made significantly fewer errors as the trials progressed. There was no significant main effect of group, and the Trial \times Group interaction was not significant (p 's > 0.05). Arm entry errors from the 1-hour and 24-hours memory test trials were analyzed with separated one-way ANOVAs. For the 1-hour memory test trial, there was no significant group effect ($p > 0.05$). The 24-hours memory test trial is shown at the right of the top graph and also in the lower graph. There was a significant group effect for the 24-hours memory performance data, $F(5,42) = 5.32$, $p < 0.001$. Post hoc tests indicated

that the groups administered 1, 5, or 10 mg/kg of tianeptine made significantly fewer arm entry errors than the groups administered vehicle (data in blue). The lower graph illustrates 24-hours memory performance in greater detail. The tianeptine-treated groups which exhibited no significant improvement in memory (0.25 and 0.5 mg/kg) are represented by the brown bars, and the tianeptine-treated groups which exhibited a significant improvement in memory (1, 5 and 10 mg/kg) are represented by the blue bars. The dashed line at 2.5 errors in both graphs indicates chance level of performance [168]. * = $p < 0.05$ relative to the vehicle-treated group.

As illustrated in Figure 1 (top), the tianeptine- and vehicle-treated groups were equivalent in their performance during the acquisition phase of the water maze task, as all groups made significantly fewer arm entry errors across the 4 training (acquisition) trials. In addition, all groups exhibited statistically equivalent performance on the short-term (1-hour) spatial memory test trial. The specific effect of pre-training tianeptine administration was revealed on the 24-hours memory test. Rats injected with the vehicle or the lowest doses of tianeptine (0.25 or 0.5 mg/kg) exhibited a deterioration of their memory at 24-hours. Rats administered the higher doses of tianeptine (1, 5, or 10 mg/kg), in contrast, exhibited intact 24-hours memory. This finding indicates that tianeptine, when administered 30 minutes prior to acquisition, produced a dose-dependent enhancement of long-term (24-hours) spatial memory in rats.

The tianeptine-mediated enhancement long-term memory is likely to be based on tianeptine's well-described enhancement of physiological measures of hippocampal function, including an enhancement of synaptic plasticity in the CA1 region. Moreover, these findings are consistent with our previous speculation that tianeptine enables hippocampus-dependent information to be stored more efficiently, thereby enhancing long-term memory under control conditions (Figure 1), as well as to protect the retrieval of the memory from being disrupted by stress [160].

6. Mechanisms Underlying Tianeptine's Procognitive and Anti-Stress Effects

Recent studies have indicated that tianeptine's therapeutic effects are associated with its modulation of the glutamatergic system [7,8,12,16,33,161,172]. Glutamate is the primary excitatory neurotransmitter of the central nervous system, and one of its roles is to regulate calcium influx by acting on postsynaptic AMPA and NMDA receptors [173]. Studies have shown that depressed patients exhibit elevated glutamate levels in plasma, CSF and post-mortem brain samples, which supports current views implicating the dysregulation of glutamate transmission in the pathogenesis of depression [92–94].

Extensive work has implicated hyperactivity of the glutamatergic system in the deleterious effects of stress on brain structure and function. Experiments conducted primarily on the hippocampus have shown that stress significantly increases glutamate levels [138,174–177], inhibits glutamate uptake [178], increases the expression and binding of glutamate receptors [179–181] and increases calcium currents [182]. Accordingly, researchers have shown that administration of NMDA receptor antagonists blocks the effects of stress on behavioral, morphological and electrophysiological measures of hippocampal function [148].

Tianeptine appears to protect the hippocampus and PFC from the deleterious effects of stress and depression by normalizing the stress-induced modulation of glutamatergic activity. For instance, tianeptine blocked the stress-induced increase in NMDA channel currents, as well as the ratio of NMDA: non-NMDA receptor currents, in the hippocampus [183]. Tianeptine also inhibited the acute

stress-induced increase in extracellular levels of glutamate in the BLA, while having no effect on the stress-induced increase in these levels in the central nuclei of the amygdala (CeA) [138]. Interestingly, as mentioned above, tianeptine had no effect on the stress-induced enhancement of LTP in the BLA [156]. This finding suggests that the stress-induced enhancement of LTP in the BLA may involve NMDA-independent forms of synaptic plasticity, such as voltage-gated calcium channel-dependent LTP [184].

In contrast to tianeptine, administration of the SSRI fluoxetine increased baseline and stress-induced levels of glutamate in the BLA and CeA [138]. This finding may explain why SSRIs are anxiogenic early in the treatment phase [101,185]. Moreover, investigators have shown that acute administration of the SSRI citalopram enhanced the acquisition of auditory fear conditioning, while chronic treatment with citalopram impaired the acquisition and expression of conditioned fear [101]. Acute treatment with tianeptine, in contrast, had no effect on auditory fear conditioning, but when given chronically, exerted effects comparable to those of citalopram. Thus, tianeptine demonstrates long-lasting anxiolytic and antidepressant effects that are similar to SSRIs, without the adverse acute effects typically found with these agents.

Tianeptine's effect on glutamatergic activity in the amygdala may play an important role in its ability to reverse the effects of chronic stress on amygdala morphology and the expression of anxiety-like behaviors. In addition to its glutamatergic modulation, tianeptine reduces the expression of corticotropin-releasing hormone (CRH) mRNA in the amygdala and the bed nucleus of the stria terminalis (BNST), a brain region that is highly innervated by amygdala fibers [186]. CRH neurotransmission in both of these regions has been implicated in the expression of anxiety-like behaviors, and several studies have reported significantly elevated CSF CRH levels in depressed patients [187–189]. If the amygdala is the site of the initiation of chronic stress-induced functional changes in other brain regions, such as the hippocampus and PFC, then tianeptine's ability to stabilize amygdala activity could underlie its widespread anti-stress effects.

Chronic stress has been shown to increase expression of the glutamate transporter, GLT-1, which is important for removing excess glutamate from synaptic regions [190]. This effect was specifically observed in the CA3 region of the hippocampus, the primary area exhibiting significant morphological alterations following chronic stress. Researchers have postulated that the up-regulation of GLT-1 levels in this region is a compensatory response to chronic elevations of extracellular glutamate levels. Importantly, tianeptine has been shown to block the stress-induced increase in hippocampal GLT-1 levels. In theory, tianeptine accomplishes this feat by normalizing stress-induced glutamate levels in the hippocampus, thereby removing the stimulus (*i.e.*, excessive glutamate) which necessitates increased expression of GLT-1.

In addition to its ability to normalize the stress-induced increase in NMDA receptor currents, tianeptine also increases basal excitatory synaptic transmission in hippocampal circuits, predominantly via enhancing AMPA EPSCs [183]. In addition to NMDA receptors, AMPA receptors play an important role in excitatory synaptic transmission and the induction of long-term synaptic plasticity [191]. Recent work has reported that tianeptine modulates the phosphorylation of AMPA receptor subunits in the hippocampus [6]. Other antidepressants, such as SSRIs and tricyclic antidepressants, have been shown to increase phosphorylation of the Ser845 site on the glutamate receptor subunit 1 (GluR1) of hippocampal AMPA receptors [192,193]. One team of investigators found that chronic, but not acute, tianeptine treatment significantly increased phosphorylation of the Ser831 and Ser845 sites on the

GluR1 subunit of AMPA receptors in the CA3 region of the hippocampus [6]. More recent work has shown that acute tianeptine significantly increased phosphorylation of the Ser831 site on the GluR1 subunit of AMPA receptors in the PFC, which was associated with tianeptine's ability to prevent the acute stress-induced impairment of LTP in the hippocampus-PFC pathway [157]. Typically, phosphorylation of the Ser831 and Ser845 sites of AMPA receptors occurs via protein kinase A (PKA) and calcium/calmodulin-dependent protein kinase II (CaMKII) or protein kinase C (PKC), respectively, and potentiates AMPA currents in the hippocampus [194,195]. Thus, the tianeptine-mediated increase in the phosphorylation of the serine sites on the GluR1 subunit of AMPA receptors could explain the finding of a tianeptine-induced enhancement of AMPA EPSCs in the study of Kole *et al.* [183], which may also be relevant toward understanding tianeptine's effectiveness as an antidepressant.

In recent work, Uzbay and colleagues found that tianeptine attenuated pentylenetetrazole (PTZ)-induced seizures [196–198] in rodents, which is consistent with its known mode of action to reduce excessive glutamatergic activity. Importantly, the investigators found that the latter effect was blocked by the administration of caffeine, a nonspecific adenosine receptor antagonist, and 8-cyclopentyl-1,3-dipropylxanthine, an A₁ receptor-specific antagonist. Administration of the A₂ receptor-specific antagonist, 8-(3-chlorostyryl) caffeine, had no effect on the tianeptine-induced delay of seizure onset. Thus, tianeptine's anticonvulsant and anxiolytic properties in rodents [98,101,199–204] and in depressed people [205,206] may involve stabilization of glutamate levels acting in concert with activation of A₁ adenosine receptors [199–202].

7. Summary and Conclusions

Considerable progress has been made in describing the physiological and behavioral sequelae that result from depression, but the specific factors responsible for its development and maintenance are not well understood. Investigators have utilized animal models of stress effects on brain and behavior to develop a better understanding of the neurobiological basis of depression, which could ultimately produce improved treatment options for the patient. We have reviewed the findings of preclinical research demonstrating that tianeptine prevents the deleterious effects of stress on physiology and behavior. Tianeptine prevents chronic stress-induced morphological changes in the hippocampus and amygdala and blocks the effects of acute stress on synaptic plasticity in the hippocampus and PFC. We have also reviewed findings demonstrating that tianeptine has procognitive effects. Tianeptine enhances hippocampus-dependent learning and memory and prevents the stress-induced impairment of such processes. Tianeptine's prevention of the adverse effects of stress on brain and behavior is likely to contribute to its effectiveness as a treatment for people suffering from depression.

Tianeptine's antidepressant effects appear to involve modulation of glutamatergic neurotransmission, which resonates with evidence implicating abnormal glutamate activity in the pathogenesis of depression. Cellular, molecular and electrophysiological studies have shown that tianeptine prevents the stress-induced rise in amygdaloid glutamate levels and blocks stress-induced changes in glutamate receptor currents and glutamate transporter expression in the hippocampus. Moreover, tianeptine potentiates AMPA receptor function, as demonstrated by increasing phosphorylation of the Ser831 and Ser845 sites on the GluR1 subunit of AMPA receptors in the hippocampus and PFC. These latter findings may explain why tianeptine enhanced long-term (24-hours) hippocampus-dependent memory retrieval (as reported here) and, more generally, how it facilitates

synaptic plasticity in the hippocampus. Other research has shown that tianeptine has anticonvulsant properties, which appear to be based on its stabilization of glutamate levels in conjunction with adenosine receptor activation.

In summary, tianeptine is a well-described antidepressant with effective actions against stress-induced deficits of the nervous system. It is as effective as SSRIs in treating depression, produces fewer adverse side effects and reduces anxious symptoms associated with depression without the need for concomitant anxiolytic therapy [18–21,207]. It is therefore relevant to note that tianeptine has been shown to ameliorate symptoms in people with post-traumatic stress disorder (PTSD) [208] and in recent work has been shown to block the effects of intense stress on behavior and cardiovascular systems in an animal model of PTSD [100]. Thus, the well-described antidepressant and memory protective properties of tianeptine indicate that, in addition to its effectiveness as a treatment in mood disorders, it potentially has broader applications, as in the treatment of anxiety.

Acknowledgements

The work in this manuscript was supported by Research Career Scientist and Merit Review Awards from the Department of Veterans Affairs to DD. We thank Adam Campbell for his technical assistance in the behavioral components of this work.

References

1. Druss, B.G.; Rask, K.; Katon, W.J. Major depression, depression treatment and quality of primary medical care. *Gen. Hosp. Psychiatry* **2008**, *30*, 20-25.
2. Thakur, M.; Blazer, D.G. Depression in long-term care. *J. Am. Med. Dir. Assoc.* **2008**, *9*, 82-87.
3. Morilak, D.A.; Frazer, A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. *Int. J. Neuropsychopharmacol.* **2004**, *7*, 193-218.
4. Barrett, B.; Byford, S.; Knapp, M. Evidence of cost-effective treatments for depression: a systematic review. *J. Affect. Disord.* **2005**, *84*, 1-13.
5. Vaswani, M.; Linda, F.K.; Ramesh, S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2003**, *27*, 85-102.
6. Svenningsson, P.; Bateup, H.; Qi, H.; Takamiya, K.; Huganir, R.L.; Spedding, M.; Roth, B.L.; McEwen, B.S.; Greengard, P. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. *Eur. J. Neurosci.* **2007**, *26*, 3509-3517.
7. Racagni, G.; Popoli, M. The pharmacological properties of antidepressants. *Int. Clin. Psychopharmacol.* **2010**, *25*, 117-131.
8. Racagni, G.; Popoli, M. Cellular and molecular mechanisms in the long-term action of antidepressants. *Dialogues Clin. Neurosci.* **2008**, *10*, 385-400.
9. Berton, O.; Nestler, E.J. New approaches to antidepressant drug discovery: beyond monoamines. *Nat. Rev. Neurosci.* **2006**, *7*, 137-151.
10. Maoz, H. Failure of first SSRI for depression--what is the next step? *Isr. J. Psychiatry Relat. Sci.* **2007**, *44*, 327-329.

11. Papakostas, G.I.; Fava, M.; Thase, M.E. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. *Biol. Psychiatry* **2008**, *63*, 699-704.
12. Brink, C.B.; Harvey, B.H.; Brand, L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. *Recent Pat. CNS Drug Discov.* **2006**, *1*, 29-41.
13. Kucia, K.; Malecki, A.; Gabryel, B.; Trzeciak, H.I. Effect of antidepressants on the phospholipase A(2) activity in plasma membranes of the rat brain cortex. *Polish J. Pharmacol.* **2003**, *55*, 5-15.
14. Pitra, P.; Tokarski, K.; Grzegorzewska, M.; Hess, G. Effects of repetitive administration of tianeptine, zinc hydroaspartate and electroconvulsive shock on the reactivity of 5-HT (7) receptors in rat hippocampus. *Pharmacol. Rep.* **2007**, *59*, 627-635.
15. Uzbay, T.I. Tianeptine: potential influences on neuroplasticity and novel pharmacological effects. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2008**, *32*, 915-924.
16. McEwen, B.S.; Chattarji, S.; Diamond, D.M.; Jay, T.M.; Reagan, L.P.; Svenningsson, P.; Fuchs, E. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. *Mol. Psychiatry* **2010**, *15*, 237-249.
17. Diamond, D.M.; Campbell, A.; Park, C.R.; Vouimba, R.M. Preclinical research on stress, memory, and the brain in the development of pharmacotherapy for depression. *Eur. Neuropsychopharmacol.* **2004**, *14* (Suppl. 5), S491-S495.
18. Atmaca, M.; Kuloglu, M.; Tezcan, E.; Buyukbayram, A. Switching to tianeptine in patients with antidepressant-induced sexual dysfunction. *Hum. Psychopharmacol. Clin. Exp.* **2003**, *18*, 277-280.
19. Bonierbale, M.; Lancon, C.; Tignol, J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. *Curr. Med. Res. Opin.* **2003**, *19*, 114-124.
20. Brion, S.; Audrain, S.; De Bodinat, C. Major depressive episodes in patients over 70 years of age. Evaluation of the efficiency and acceptability of tianeptine and mianserin. *Presse Med.* **1996**, *25*, 461-468.
21. Szadoczky, E.; Furedi, J. Efficacy and acceptability of tianeptine and sertraline in the acute treatment phase of depression. *Enceph.-Re. De Psychiatr. Clin. Biol. Ther.* **2002**, *28*, 343-348.
22. Invernizzi, G.; Aguglia, E.; Bertolino, A.; Casacchia, M.; Ciani, N.; Marchesi, G.F.; Nardini, M.; Rapisarda, V. The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs. amitriptyline. *Neuropsychobiology* **1994**, *30*, 85-93.
23. Hindmarch, I. Expanding the horizons of depression: beyond the monoamine hypothesis. *Hum. Psychopharmacol.* **2001**, *16*, 203-218.
24. Pacher, P.; Kecskemeti, V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? *Curr. Med. Chem.* **2004**, *11*, 925-943.
25. Cole, J.; Toga, A.W.; Hojatkashani, C.; Thompson, P.; Costafreda, S.G.; Cleare, A.J.; Williams, S.C.; Bullmore, E.T.; Scott, J.L.; Mitterschiffthaler, M.T.; *et al.* Subregional hippocampal deformations in major depressive disorder. *J. Affect. Disord.* **2010**, doi:10.1016/j.jad.2010.03.004.
26. Bremner, J.D.; Vythilingam, M.; Vermetten, E.; Anderson, G.; Newcomer, J.W.; Charney, D.S. Effects of glucocorticoids on declarative memory function in major depression. *Biol. Psychiatry* **2004**, *55*, 811-815.
27. Campbell, S.; Macqueen, G. The role of the hippocampus in the pathophysiology of major depression. *J. Psychiatry Neurosci.* **2004**, *29*, 417-426.

28. Esch, T.; Stefano, G.B.; Fricchione, G.L.; Benson, H. The role of stress in neurodegenerative diseases and mental disorders. *Neuro Endocrinol. Lett.* **2002**, *23*, 199-208.
29. Pittenger, C.; Duman, R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. *Neuropsychopharmacology* **2008**, *33*, 88-109.
30. McEwen, B.S.; Olie, J.P. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. *Mol. Psychiatry* **2005**, *10*, 525-537.
31. Fuchs, E.; Czeh, B.; Kole, M.H.; Michaelis, T.; Lucassen, P.J. Alterations of neuroplasticity in depression: the hippocampus and beyond. *Eur. Neuropsychopharmacol.* **2004**, *14* (Suppl. 5), S481-S490.
32. Sheline, Y.I. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. *Biol. Psychiatry* **2000**, *48*, 791-800.
33. Kasper, S.; McEwen, B.S. Neurobiological and clinical effects of the antidepressant tianeptine. *CNS Drugs* **2008**, *22*, 15-26.
34. Squire, L.R.; Stark, C.E.; Clark, R.E. The medial temporal lobe. *Annu. Rev. Neurosci.* **2004**, *27*, 279-306.
35. Eichenbaum, H. Hippocampus: cognitive processes and neural representations that underlie declarative memory. *Neuron* **2004**, *44*, 109-120.
36. Broadbent, N.J.; Squire, L.R.; Clark, R.E. Spatial memory, recognition memory, and the hippocampus. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 14515-14520.
37. Broadbent, N.J.; Squire, L.R.; Clark, R.E. Reversible hippocampal lesions disrupt water maze performance during both recent and remote memory tests. *Learn. Mem.* **2006**, *13*, 187-191.
38. Kaut, K.P.; Bunsey, M.D. The effects of lesions to the rat hippocampus or rhinal cortex on olfactory and spatial memory: retrograde and anterograde findings. *Cogn. Affect. Behav. Neurosci.* **2001**, *1*, 270-286.
39. Moser, M.B.; Moser, E.I. Distributed encoding and retrieval of spatial memory in the hippocampus. *J. Neurosci.* **1998**, *18*, 7535-7542.
40. Moses, S.N.; Cole, C.; Ryan, J.D. Relational memory for object identity and spatial location in rats with lesions of perirhinal cortex, amygdala and hippocampus. *Brain Res. Bull.* **2005**, *65*, 501-512.
41. Winocur, G.; Moscovitch, M.; Caruana, D.A.; Binns, M.A. Retrograde amnesia in rats with lesions to the hippocampus on a test of spatial memory. *Neuropsychologia* **2005**, *43*, 1580-1590.
42. Blumenfeld, R.S.; Ranganath, C. Prefrontal cortex and long-term memory encoding: an integrative review of findings from neuropsychology and neuroimaging. *Neuroscientist* **2007**, *13*, 280-291.
43. Pare, D.; Quirk, G.J.; LeDoux, J.E. New vistas on amygdala networks in conditioned fear. *J. Neurophysiol.* **2004**, *92*, 1-9.
44. Phelps, E.A.; LeDoux, J.E. Contributions of the amygdala to emotion processing: from animal models to human behavior. *Neuron* **2005**, *48*, 175-187.
45. LeDoux, J.E. Emotional memory: in search of systems and synapses. *Ann. N. Y. Acad. Sci.* **1993**, *702*, 149-157.
46. Kanner, A.M. Structural MRI changes of the brain in depression. *Clin. EEG Neurosci.* **2004**, *35*, 46-52.
47. Maletic, V.; Robinson, M.; Oakes, T.; Iyengar, S.; Ball, S.G.; Russell, J. Neurobiology of depression: an integrated view of key findings. *Int. J. Clin. Pract.* **2007**, *61*, 2030-2040.

48. Vasic, N.; Walter, H.; Hose, A.; Wolf, R.C. Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: A voxel-based morphometry study. *J. Affect. Disord.* **2008**, *109*, 107-116.
49. Mondal, S.; Sharma, V.K.; Das, S.; Goswami, U.; Gandhi, A. Neuro-cognitive functions in patients of major depression. *Indian J. Physiol. Pharmacol.* **2007**, *51*, 69-75.
50. Ebmeier, K.; Rose, E.; Steele, D. Cognitive impairment and fMRI in major depression. *Neurotox. Res.* **2006**, *10*, 87-92.
51. Drevets, W.C. Neuroimaging studies of mood disorders. *Biol. Psychiatry* **2000**, *48*, 813-829.
52. Frodl, T.; Meisenzahl, E.; Zetzsche, T.; Bottlender, R.; Born, C.; Groll, C.; Jager, M.; Leinsinger, G.; Hahn, K.; Moller, H.J. Enlargement of the amygdala in patients with a first episode of major depression. *Biol. Psychiatry* **2002**, *51*, 708-714.
53. Siegle, G.J.; Carter, C.S.; Thase, M.E. Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. *Am. J. Psychiatry* **2006**, *163*, 735-738.
54. Nemeroff, C.B.; Vale, W.W. The neurobiology of depression: inroads to treatment and new drug discovery. *J. Clin. Psychiatry* **2005**, *66* (Suppl. 7), 5-13.
55. Kendler, K.S.; Karkowski, L.M.; Prescott, C.A. Causal relationship between stressful life events and the onset of major depression. *Am. J. Psychiatry* **1999**, *156*, 837-841.
56. Nestler, E.J.; Gould, E.; Manji, H. Preclinical models: status of basic research in depression. *Biol. Psychiatry* **2002**, *52*, 503-528.
57. Anisman, H.; Matheson, K. Stress, depression, and anhedonia: caveats concerning animal models. *Neurosci. Biobehav. Rev.* **2005**, *29*, 525-546.
58. Gambarana, C.; Scheggi, S.; Tagliamonte, A.; Tolu, P.; De Montis, M.G. Animal models for the study of antidepressant activity. *Brain Res. Brain Res. Protoc.* **2001**, *7*, 11-20.
59. McArthur, R.; Borsini, F. Animal models of depression in drug discovery: A historical perspective. *Pharmacol. Biochem. Behav.* **2006**, *84*, 436-452.
60. Conrad, C.D.; Magarinos, A.M.; LeDoux, J.E.; McEwen, B.S. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. *Behav. Neurosci.* **1999**, *113*, 902-913.
61. Kole, M.H.; Costoli, T.; Koolhaas, J.M.; Fuchs, E. Bidirectional shift in the cornu ammonis 3 pyramidal dendritic organization following brief stress. *Neuroscience* **2004**, *125*, 337-347.
62. Lambert, K.G.; Buckelew, S.K.; Staffiso-Sandoz, G.; Gaffga, S.; Carpenter, W.; Fisher, J.; Kinsley, C.H. Activity-stress induces atrophy of apical dendrites of hippocampal pyramidal neurons in male rats. *Physiol. Behav.* **1998**, *65*, 43-49.
63. Magarinos, A.M.; McEwen, B.S. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: comparison of stressors. *Neuroscience* **1995**, *69*, 83-88.
64. Magarinos, A.M.; McEwen, B.S.; Flugge, G.; Fuchs, E. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. *J. Neurosci.* **1996**, *16*, 3534-3540.
65. McKittrick, C.R.; Magarinos, A.M.; Blanchard, D.C.; Blanchard, R.J.; McEwen, B.S.; Sakai, R.R. Chronic social stress reduces dendritic arbors in CA3 of hippocampus and decreases binding to serotonin transporter sites. *Synapse* **2000**, *36*, 85-94.

66. Vyas, A.; Mitra, R.; Shankaranarayana Rao, B.S.; Chattarji, S. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. *J. Neurosci.* **2002**, *22*, 6810-6818.
67. Watanabe, Y.; Gould, E.; McEwen, B.S. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. *Brain Res.* **1992**, *588*, 341-345.
68. Cerqueira, J.J.; Mailliet, F.; Almeida, O.F.; Jay, T.M.; Sousa, N. The prefrontal cortex as a key target of the maladaptive response to stress. *J. Neurosci.* **2007**, *27*, 2781-2787.
69. Cook, S.C.; Wellman, C.L. Chronic stress alters dendritic morphology in rat medial prefrontal cortex. *J. Neurobiol.* **2004**, *60*, 236-248.
70. Radley, J.J.; Rocher, A.B.; Miller, M.; Janssen, W.G.; Liston, C.; Hof, P.R.; McEwen, B.S.; Morrison, J.H. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. *Cereb. Cortex* **2006**, *16*, 313-320.
71. Liston, C.; Miller, M.M.; Goldwater, D.S.; Radley, J.J.; Rocher, A.B.; Hof, P.R.; Morrison, J.H.; McEwen, B.S. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. *J. Neurosci.* **2006**, *26*, 7870-7874.
72. Radley, J.J.; Rocher, A.B.; Janssen, W.G.; Hof, P.R.; McEwen, B.S.; Morrison, J.H. Reversibility of apical dendritic retraction in the rat medial prefrontal cortex following repeated stress. *Exp. Neurol.* **2005**, *196*, 199-203.
73. Bloss, E.B.; Janssen, W.G.; McEwen, B.S.; Morrison, J.H. Interactive effects of stress and aging on structural plasticity in the prefrontal cortex. *J. Neurosci.* **2010**, *30*, 6726-6731.
74. Vyas, A.; Jadhav, S.; Chattarji, S. Prolonged behavioral stress enhances synaptic connectivity in the basolateral amygdala. *Neuroscience* **2006**, *143*, 387-393.
75. Zoladz, P.R.; Conrad, C.D.; Fleshner, M.; Diamond, D.M. Acute episodes of predator exposure in conjunction with chronic social instability as an animal model of post-traumatic stress disorder. *Stress* **2008**, *11*, 259-281.
76. Sunanda; Rao, B.S.S.; Raju, T.R. Chronic restraint stress impairs acquisition and retention of spatial memory task in rats. *Curr. Sci.* **2000**, *79*, 1581-1584.
77. Sousa, N.; Lukoyanov, N.V.; Madeira, M.D.; Almeida, O.F.; Paula-Barbosa, M.M. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. *Neuroscience* **2000**, *97*, 253-266.
78. Park, C.R.; Campbell, A.M.; Diamond, D.M. Chronic psychosocial stress impairs learning and memory and increases sensitivity to yohimbine in adult rats. *Biol. Psychiatry* **2001**, *50*, 994-1004.
79. Luine, V.; Villegas, M.; Martinez, C.; McEwen, B.S. Repeated stress causes reversible impairments of spatial memory performance. *Brain Res.* **1994**, *639*, 167-170.
80. Krugers, H.J.; Douma, B.R.K.; Andringa, G.; Bohus, B.; Korf, J.; Luiten, P.G.M. Exposure to chronic psychosocial stress and corticosterone in the rat: Effects on spatial discrimination learning and hippocampal protein kinase C gamma immunoreactivity. *Hippocampus* **1997**, *7*, 427-436.
81. Bodnoff, S.R.; Humphreys, A.G.; Lehman, J.C.; Diamond, D.M.; Rose, G.M.; Meaney, M.J. Enduring effects of chronic corticosterone treatment on spatial learning, synaptic plasticity, and hippocampal neuropathology in young and mid-aged rats. *J. Neurosci.* **1995**, *15*, 61-69.

82. Sandi, C.; Merino, J.J.; Cordero, M.I.; Touyarot, K.; Venero, C. Effects of chronic stress on contextual fear conditioning and the hippocampal expression of the neural cell adhesion molecule, its polysialylation, and L1. *Neuroscience* **2001**, *102*, 329-339.
83. Vyas, A.; Pillai, A.G.; Chattarji, S. Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior. *Neuroscience* **2004**, *128*, 667-673.
84. Bloss, E.B.; Janssen, W.G.; McEwen, B.S.; Morrison, J.H. Interactive effects of stress and aging on structural plasticity in the prefrontal cortex. *J. Neurosci.* **2010**, *30*, 6726-6731.
85. Magarinos, A.M.; Orchinik, M.; McEwen, B.S. Morphological changes in the hippocampal CA3 region induced by non-invasive glucocorticoid administration: a paradox. *Brain Res.* **1998**, *809*, 314-318.
86. Woolley, C.S.; Gould, E.; McEwen, B.S. Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. *Brain Res.* **1990**, *531*, 225-231.
87. Wellman, C.L. Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. *J. Neurobiol.* **2001**, *49*, 245-253.
88. Magarinos, A.M.; McEwen, B.S. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. *Neuroscience* **1995**, *69*, 89-98.
89. Watanabe, Y.; Gould, E.; Cameron, H.A.; Daniels, D.C.; McEwen, B.S. Phenytoin prevents stress- and corticosterone-induced atrophy of CA3 pyramidal neurons. *Hippocampus* **1992**, *2*, 431-435.
90. Gillespie, C.F.; Nemeroff, C.B. Hypercortisolemia and depression. *Psychosom. Med.* **2005**, *67* (Suppl. 1), S26-S28.
91. Pariante, C.M.; Miller, A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. *Biol. Psychiatry* **2001**, *49*, 391-404.
92. Kendell, S.F.; Krystal, J.H.; Sanacora, G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. *Expert. Opin. Ther. Targets.* **2005**, *9*, 153-168.
93. Krystal, J.H.; Sanacora, G.; Blumberg, H.; Anand, A.; Charney, D.S.; Marek, G.; Epperson, C.N.; Goddard, A.; Mason, G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. *Mol. Psychiatry* **2002**, *7* (Suppl. 1), S71-S80.
94. Sanacora, G.; Gueorguieva, R.; Epperson, C.N.; Wu, Y.T.; Appel, M.; Rothman, D.L.; Krystal, J.H.; Mason, G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. *Arch. Gen. Psychiatry* **2004**, *61*, 705-713.
95. Czeh, B.; Michaelis, T.; Watanabe, T.; Frahm, J.; de Biurrun, G.; Van Kampen, M.; Bartolomucci, A.; Fuchs, E. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 12796-12801.
96. Magarinos, A.M.; Deslandes, A.; McEwen, B.S. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. *Eur. J. Pharmacol.* **1999**, *371*, 113-122.
97. Watanabe, Y.; Gould, E.; Daniels, D.C.; Cameron, H.; McEwen, B.S. Tianeptine attenuates stress-induced morphological changes in the hippocampus. *Eur. J. Pharmacol.* **1992**, *222*, 157-162.

98. Pillai, A.G.; Munoz, C.; Chattarji, S. The antidepressant tianeptine prevents the dendritic hypertrophy in the amygdala and increase in anxiety induced by chronic stress in the rat. *Soc. Neurosci. Abst.* **2004**, *34*, 762.1.
99. Conrad, C.D.; Galea, L.A.M.; Kuroda, Y.; McEwen, B.S. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. *Behav. Neurosci.* **1996**, *110*, 1321-1334.
100. Zoladz, P.R.; Halonen, J.; Munoz, C.; Diamond, D.M. Daily tianeptine treatment initiated after stress onset blocks the effects of chronic psychosocial stress on physiology and behavior in an animal model of PTSD. *Soc. Neuro. Sci. Abst.* **2007**, *37*, 171.17.
101. Burghardt, N.S.; Sullivan, G.M.; McEwen, B.S.; Gorman, J.M.; LeDoux, J.E. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: A comparison with tianeptine. *Biol. Psychiatry* **2004**, *55*, 1171-1178.
102. Ehninger, D.; Kempermann, G. Neurogenesis in the adult hippocampus. *Cell Tissue Res.* **2008**, *331*, 243-250.
103. Gould, E.; Beylin, A.; Tanapat, P.; Reeves, A.; Shors, T.J. Learning enhances adult neurogenesis in the hippocampal formation. *Nat. Neurosci.* **1999**, *2*, 260-265.
104. Shors, T.J.; Miesegaes, G.; Beylin, A.; Zhao, M.; Rydel, T.; Gould, E. Neurogenesis in the adult is involved in the formation of trace memories. *Nature* **2001**, *410*, 372-376.
105. Dranovsky, A.; Hen, R. Hippocampal neurogenesis: regulation by stress and antidepressants. *Biol. Psychiatry* **2006**, *59*, 1136-1143.
106. Duman, R.S. Depression: a case of neuronal life and death? *Biol. Psychiatry* **2004**, *56*, 140-145.
107. Henn, F.A.; Vollmayr, B. Neurogenesis and depression: etiology or epiphenomenon? *Biol. Psychiatry* **2004**, *56*, 146-150.
108. Jacobs, B.L.; Praag, H.; Gage, F.H. Adult brain neurogenesis and psychiatry: a novel theory of depression. *Mol. Psychiatry* **2000**, *5*, 262-269.
109. Sapolsky, R.M. Is impaired neurogenesis relevant to the affective symptoms of depression? *Biol. Psychiatry* **2004**, *56*, 137-139.
110. Gould, E.; Tanapat, P. Stress and hippocampal neurogenesis. *Biol. Psychiatry* **1999**, *46*, 1472-1479.
111. Heine, V.M.; Maslam, S.; Zareno, J.; Joels, M.; Lucassen, P.J. Suppressed proliferation and apoptotic changes in the rat dentate gyrus after acute and chronic stress are reversible. *Eur. J. Neurosci.* **2004**, *19*, 131-144.
112. Heine, V.M.; Zareno, J.; Maslam, S.; Joels, M.; Lucassen, P.J. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. *Eur. J. Neurosci.* **2005**, *21*, 1304-1314.
113. Pham, K.; Nacher, J.; Hof, P.R.; McEwen, B.S. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. *Eur. J. Neurosci.* **2003**, *17*, 879-886.
114. Rosenbrock, H.; Koros, E.; Bloching, A.; Podhorna, J.; Borsini, F. Effect of chronic intermittent restraint stress on hippocampal expression of marker proteins for synaptic plasticity and progenitor cell proliferation in rats. *Brain Res.* **2005**, *1040*, 55-63.

115. Schmidt, H.D.; Duman, R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. *Behav. Pharmacol.* **2007**, *18*, 391-418.
116. Lucassen, P.J.; Vollmann-Honsdorf, G.K.; Gleisberg, M.; Czeh, B.; de Kloet, E.R.; Fuchs, E. Chronic psychosocial stress differentially affects apoptosis in hippocampal subregions and cortex of the adult tree shrew. *Eur. J. Neurosci.* **2001**, *14*, 161-166.
117. Zhao, H.; Xu, H.; Xu, X.; Young, D. Predatory stress induces hippocampal cell death by apoptosis in rats. *Neurosci. Lett.* **2007**, *421*, 115-120.
118. Lucassen, P.J.; Fuchs, E.; Czeh, B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. *Biol. Psychiatry* **2004**, *55*, 789-796.
119. Huang, E.J.; Reichardt, L.F. Neurotrophins: roles in neuronal development and function. *Annu. Rev. Neurosci.* **2001**, *24*, 677-736.
120. Smith, M.A.; Makino, S.; Kvetnansky, R.; Post, R.M. Effects of stress on neurotrophic factor expression in the rat brain. *Ann. N. Y. Acad. Sci.* **1995**, *771*, 234-239.
121. Smith, M.A.; Makino, S.; Kvetnansky, R.; Post, R.M. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. *J. Neurosci.* **1995**, *15*, 1768-1777.
122. Ueyama, T.; Kawai, Y.; Nemoto, K.; Sekimoto, M.; Tone, S.; Senba, E. Immobilization stress reduced the expression of neurotrophins and their receptors in the rat brain. *Neurosci. Res.* **1997**, *28*, 103-110.
123. Alfonso, J.; Frick, L.R.; Silberman, D.M.; Palumbo, M.L.; Genaro, A.M.; Frasch, A.C. Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. *Biol. Psychiatry* **2006**, *59*, 244-251.
124. Barrientos, R.M.; Sprunger, D.B.; Campeau, S.; Higgins, E.A.; Watkins, L.R.; Rudy, J.W.; Maier, S.F. Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. *Neuroscience* **2003**, *121*, 847-853.
125. Kozlovsky, N.; Matar, M.A.; Kaplan, Z.; Kotler, M.; Zohar, J.; Cohen, H. Long-term downregulation of BDNF mRNA in rat hippocampal CA1 subregion correlates with PTSD-like behavioural stress response. *Int. J. Neuropsychopharmacology* **2007**, *10*, 741-758.
126. Murakami, S.; Imbe, H.; Morikawa, Y.; Kubo, C.; Senba, E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. *Neurosci. Res.* **2005**, *53*, 129-139.
127. Pizarro, J.M.; Lumley, L.A.; Medina, W.; Robison, C.L.; Chang, W.E.; Alagappan, A.; Bah, M.J.; Dawood, M.Y.; Shah, J.D.; Mark, B.; *et al.* Acute social defeat reduces neurotrophin expression in brain cortical and subcortical areas in mice. *Brain Res.* **2004**, *1025*, 10-20.
128. Rasmusson, A.M.; Shi, L.; Duman, R. Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. *Neuropsychopharmacology* **2002**, *27*, 133-142.
129. Roceri, M.; Cirulli, F.; Pessina, C.; Peretto, P.; Racagni, G.; Riva, M.A. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. *Biol. Psychiatry* **2004**, *55*, 708-714.

130. Roceri, M.; Hendriks, W.; Racagni, G.; Ellenbroek, B.A.; Riva, M.A. Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. *Mol. Psychiatry* **2002**, *7*, 609-616.
131. Scaccianoce, S.; Del Bianco, P.; Caricasole, A.; Nicoletti, F.; Catalani, A. Relationship between learning, stress and hippocampal brain-derived neurotrophic factor. *Neuroscience* **2003**, *121*, 825-828.
132. Shimizu, E.; Hashimoto, K.; Okamura, N.; Koike, K.; Komatsu, N.; Kumakiri, C.; Nakazato, M.; Watanabe, H.; Shinoda, N.; Okada, S.; *et al.* Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. *Biol. Psychiatry* **2003**, *54*, 70-75.
133. Karege, F.; Perret, G.; Bondolfi, G.; Schwald, M.; Bertschy, G.; Aubry, J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. *Psychiatry Res.* **2002**, *109*, 143-148.
134. Aydemir, C.; Yalcin, E.S.; Aksaray, S.; Kisa, C.; Yildirim, S.G.; Uzbay, T.; Goka, E. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2006**, *30*, 1256-1260.
135. Reagan, L.P.; Hendry, R.M.; Reznikov, L.R.; Piroli, G.G.; Wood, G.E.; McEwen, B.S.; Grillo, C.A. Tianeptine increases brain-derived neurotrophic factor expression in the rat amygdala. *Eur. J. Pharmacol.* **2007**, *565*, 68-75.
136. Castren, E. Neurotrophic effects of antidepressant drugs. *Curr. Opin. Pharmacol.* **2004**, *4*, 58-64.
137. Chen, B.; Dowlatshahi, D.; MacQueen, G.M.; Wang, J.F.; Young, L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. *Biol. Psychiatry* **2001**, *50*, 260-265.
138. Reznikov, L.R.; Grillo, C.A.; Piroli, G.G.; Pasumarthi, R.K.; Reagan, L.P.; Fadel, J. Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment. *Eur. J. Neurosci.* **2007**, *25*, 3109-3114.
139. McEwen, B.S. Mood disorders and allostatic load. *Biol. Psychiatry* **2003**, *54*, 200-207.
140. Raymond, C.R. LTP forms 1, 2 and 3: different mechanisms for the "long" in long-term potentiation. *Trends Neurosci.* **2007**, *30*, 167-175.
141. Kim, J.J.; Song, E.Y.; Kosten, T.A. Stress effects in the hippocampus: synaptic plasticity and memory. *Stress* **2006**, *9*, 1-11.
142. Diamond, D.M.; Park, C.R.; Woodson, J.C. Stress generates emotional memories and retrograde amnesia by inducing an endogenous form of hippocampal LTP. *Hippocampus* **2004**, *14*, 281-291.
143. Diamond, D.M.; Park, C.R.; Campbell, A.M.; Woodson, J.C. Competitive interactions between endogenous LTD and LTP in the hippocampus underlie the storage of emotional memories and stress-induced amnesia. *Hippocampus* **2005**, *15*, 1006-1025.
144. Diamond, D.M.; Campbell, A.M.; Park, C.R.; Halonen, J.; Zoladz, P.R. The temporal dynamics model of emotional memory processing: a synthesis on the neurobiological basis of stress-induced amnesia, flashbulb and traumatic memories, and the Yerkes-Dodson Law. *Neural Plast.* **2007**, *60803*.

145. Korz, V.; Frey, J.U. Stress-related modulation of hippocampal long-term potentiation in rats: Involvement of adrenal steroid receptors. *J. Neurosci.* **2003**, *23*, 7281-7287.
146. Mailliet, F.; Qi, H.; Rocher, C.; Spedding, M.; Svenningsson, P.; Jay, T.M. Protection of stress-induced impairment of hippocampal/prefrontal LTP through blockade of glucocorticoid receptors: implication of MEK signaling. *Exp. Neurol.* **2008**, *211*, 593-596.
147. McEwen, B.S. Corticosteroids and hippocampal plasticity. *Ann. N. Y. Acad. Sci.* **1994**, *746*, 134-142.
148. Kim, J.J.; Foy, M.R.; Thompson, R.F. Behavioral stress modifies hippocampal plasticity through N-methyl-D-aspartate receptor activation. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 4750-4753.
149. McEwen, B.S. Stress and hippocampal plasticity. *Ann. Rev. Neurosci.* **1999**, *22*, 105-122.
150. Popoli, M.; Gennarelli, M.; Racagni, G. Modulation of synaptic plasticity by stress and antidepressants. *Bipolar Disord.* **2002**, *4*, 166-182.
151. Akirav, I.; Richter-Levin, G. Mechanisms of amygdala modulation of hippocampal plasticity. *J. Neurosci.* **2002**, *22*, 9912-9921.
152. Akirav, I.; Richter-Levin, G. Biphasic modulation of hippocampal plasticity by behavioral stress and basolateral amygdala stimulation in the rat. *J. Neurosci.* **1999**, *19*, 10530-10535.
153. Jay, T.M.; Rocher, C.; Hotte, M.; Naudon, L.; Gurden, H.; Spedding, M. Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: Importance for psychiatric diseases. *Neurotox. Res.* **2004**, *6*, 233-244.
154. Rocher, C.; Spedding, M.; Munoz, C.; Jay, T.M. Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. *Cereb. Cortex* **2004**, *14*, 224-229.
155. Shakesby, A.C.; Anwyl, R.; Rowan, M.J. Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents. *J. Neurosci.* **2002**, *22*, 3638-3644.
156. Vouimba, R.M.; Munoz, C.; Diamond, D.M. Differential effects of predator stress and the antidepressant tianeptine on physiological plasticity in the hippocampus and basolateral amygdala. *Stress* **2006**, *9*, 29-40.
157. Qi, H.; Mailliet, F.; Spedding, M.; Rocher, C.; Zhang, X.; Delagrangé, P.; McEwen, B.; Jay, T.M.; Svenningsson, P. Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. *Neuropharmacology* **2009**, *56*, 37-46.
158. Kim, J.J.; Diamond, D.M. The stressed hippocampus, synaptic plasticity and lost memories. *Nat. Rev. Neurosci.* **2002**, *3*, 453-462.
159. Zoladz, P.R.; Diamond, D.M. Linear and non-linear dose-response functions reveal a hormetic relationship between stress and learning. *Dose Response* **2008**, *7*, 132-148.
160. Campbell, A.M.; Park, C.R.; Zoladz, P.R.; Munoz, C.; Fleshner, M.; Diamond, D.M. Pre-training administration of tianeptine, but not propranolol, protects hippocampus-dependent memory from being impaired by predator stress. *Eur. Neuropsychopharmacol.* **2008**, *18*, 87-98.
161. Zoladz, P.R.; Park, C.R.; Munoz, C.; Fleshner, M.; Diamond, D.M. Tianeptine: an antidepressant with memory-protective properties. *Curr. Neuropharmacol.* **2008**, *6*, 311-321.
162. Jaffard, R.; Mocaer, E.; Poignant, J.C.; Micheau, J.; Marighetto, A.; Meunier, M.; Beracochea, D. Effects of tianeptine on spontaneous alternation, simple and concurrent spatial discrimination learning and on alcohol-induced alternation deficits in mice. *Behav. Pharmacol.* **1991**, *2*, 37-46.

163. Meneses, A. Tianeptine: 5-HT uptake sites and 5-HT₁₋₇ receptors modulate memory formation in an autoshaping Pavlovian/instrumental task. *Neurosci. Biobehav. Rev.* **2002**, *26*, 309-319.
164. Zoladz, P.R.; Campbell, A.M.; Park, C.R.; Schaefer, D.; Danysz, W.; Diamond, D.M. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. *Pharmacol. Biochem. Behav.* **2006**, *85*, 298-306.
165. Park, C.R.; Zoladz, P.R.; Conrad, C.D.; Fleshner, M.; Diamond, D.M. Acute predator stress impairs the consolidation and retrieval of hippocampus-dependent memory in male and female rats. *Learn. Mem.* **2008**, *15*, 271-280.
166. Conboy, L.; Tanrikut, C.; Zoladz, P.R.; Campbell, A.M.; Park, C.R.; Gabriel, C.; Mocaer, E.; Sandi, C.; Diamond, D.M. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. *Int. J. Neuropsychopharmacol.* **2009**, *12*, 329-341.
167. Zoladz, P.R.; Woodson, J.C.; Haynes, V.F.; Diamond, D.M. Activation of a remote (1-year old) emotional memory interferes with the retrieval of a newly formed hippocampus-dependent memory in rats. *Stress* **2010**, *13*, 36-52.
168. Diamond, D.M.; Park, C.R.; Heman, K.L.; Rose, G.M. Exposing rats to a predator impairs spatial working memory in the radial arm water maze. *Hippocampus* **1999**, *9*, 542-552.
169. Sandi, C.; Woodson, J.C.; Haynes, V.F.; Park, C.R.; Touyarot, K.; Lopez-Fernandez, M.A.; Venero, C.; Diamond, D.M. Acute stress-induced impairment of spatial memory is associated with decreased expression of neural cell adhesion molecule in the hippocampus and prefrontal cortex. *Biol. Psychiatry* **2005**, *57*, 856-864.
170. Diamond, D.M.; Campbell, A.M.; Park, C.R.; Woodson, J.C.; Conrad, C.D.; Bachstetter, A.D.; Mervis, R.F. Influence of predator stress on the consolidation *versus* retrieval of long-term spatial memory and hippocampal spinogenesis. *Hippocampus* **2006**, *16*, 571-576.
171. Park, C.R.; Campbell, A.M.; Woodson, J.C.; Smith, T.P.; Fleshner, M.; Diamond, D.M. Permissive influence of stress in the expression of a U-shaped relationship between serum corticosterone levels and spatial memory errors in rats. *Dose Response* **2006**, *4*, 55-74.
172. Musazzi, L.; Milanese, M.; Farisello, P.; Zappettini, S.; Tardito, D.; Barbiero, V.S.; Bonifacino, T.; Mallei, A.; Baldelli, P.; Racagni, G.; *et al.* Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. *PLoS ONE* **2010**, *5*, e8566.
173. Riedel, G.; Platt, B.; Micheau, J. Glutamate receptor function in learning and memory. *Behav. Brain Res.* **2003**, *140*, 1-47.
174. Bagley, J.; Moghaddam, B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. *Neuroscience* **1997**, *77*, 65-73.
175. Lowy, M.T.; Gault, L.; Yamamoto, B.K. Adrenalectomy attenuates stress-induced elevations in extracellular glutamate concentrations in the hippocampus. *J. Neurochem.* **1993**, *61*, 1957-1960.
176. Lowy, M.T.; Wittenberg, L.; Yamamoto, B.K. Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. *J. Neurochem.* **1995**, *65*, 268-274.

177. Moghaddam, B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. *J. Neurochem.* **1993**, *60*, 1650-1657.
178. Yang, C.H.; Huang, C.C.; Hsu, K.S. Behavioral stress enhances hippocampal CA1 long-term depression through the blockade of the glutamate uptake. *J. Neurosci.* **2005**, *25*, 4288-4293.
179. Bartanusz, V.; Aubry, J.M.; Pagliusi, S.; Jezova, D.; Baffi, J.; Kiss, J.Z. Stress-induced changes in messenger RNA levels of N-methyl-D-aspartate and AMPA receptor subunits in selected regions of the rat hippocampus and hypothalamus. *Neuroscience* **1995**, *66*, 247-252.
180. Krugers, H.J.; Koolhaas, J.M.; Bohus, B.; Korf, J. A single social stress-experience alters glutamate receptor-binding in rat hippocampal CA3 area. *Neurosci. Lett.* **1993**, *154*, 73-77.
181. McEwen, B.S.; Magarinos, A.M.; Reagan, L.P. Structural plasticity and tianeptine: cellular and molecular targets. *Eur. Psychiatry* **2002**, *17*, S318- S330.
182. Joels, M.; Velzing, E.; Nair, S.; Verkuyl, J.M.; Karst, H. Acute stress increases calcium current amplitude in rat hippocampus: temporal changes in physiology and gene expression. *Eur. J. Neurosci.* **2003**, *18*, 1315-1324.
183. Kole, M.H.; Swan, L.; Fuchs, E. The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. *Eur. J. Neurosci.* **2002**, *16*, 807-816.
184. Krugers, H.J.; Alfarez, D.N.; Karst, H.; Parashkouhi, K.; van Gemert, N.; Joels, M. Corticosterone shifts different forms of synaptic potentiation in opposite directions. *Hippocampus* **2005**, *15*, 697-703.
185. Goldstein, B.J.; Goodnick, P.J. Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics. *J. Psychopharmacol.* **1998**, *12*, S55-S87.
186. Kim, S.J.; Park, S.H.; Choi, S.H.; Moon, B.H.; Lee, K.J.; Kang, S.W.; Lee, M.S.; Choi, S.H.; Chun, B.G.; Shin, K.H. Effects of repeated tianeptine treatment on CRF mRNA expression in non-stressed and chronic mild stress-exposed rats. *Neuropharmacology* **2006**, *50*, 824-833.
187. Holsboer, F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. *J. Psychiatr. Res.* **1999**, *33*, 181-214.
188. Kasckow, J.W.; Baker, D.; Geraciotti, T.D., Jr. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. *Peptides* **2001**, *22*, 845-851.
189. Strohle, A.; Holsboer, F. Stress responsive neurohormones in depression and anxiety. *Pharmacopsychiatry* **2003**, *36* (Suppl. 3), S207-S214.
190. Reagan, L.P.; Rosell, D.R.; Wood, G.E.; Spedding, M.; Munoz, C.; Rothstein, J.; McEwen, B.S. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 2179-2184.
191. Rao, V.R.; Finkbeiner, S. NMDA and AMPA receptors: old channels, new tricks. *Trends Neurosci.* **2007**, *30*, 284-291.
192. Svenningsson, P.; Tzavara, E.T.; Witkin, J.M.; Fienberg, A.A.; Nomikos, G.G.; Greengard, P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 3182-3187.

193. Du, J.; Suzuki, K.; Wei, Y.; Wang, Y.; Blumenthal, R.; Chen, Z.; Falke, C.; Zarate, C.A., Jr.; Manji, H.K. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. *Neuropsychopharmacology* **2007**, *32*, 793-802.
194. Barria, A.; Muller, D.; Derkach, V.; Griffith, L.C.; Soderling, T.R. Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. *Science* **1997**, *276*, 2042-2045.
195. Roche, K.W.; O'Brien, R.J.; Mammen, A.L.; Bernhardt, J.; Huganir, R.L. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. *Neuron* **1996**, *16*, 1179-1188.
196. Uzbay, T.; Kayir, H.; Celik, T.; Yuksel, N. Acute and chronic tianeptine treatments attenuate ethanol withdrawal syndrome in rats. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2006**, *30*, 478-485.
197. Ceyhan, M.; Kayir, H.; Uzbay, I.T. Investigation of the effects of tianeptine and fluoxetine on pentylentetrazole-induced seizures in rats. *J. Psychiatr. Res.* **2005**, *39*, 191-196.
198. Uzbay, T.I.; Kayir, H.; Ceyhan, M. Effects of tianeptine on onset time of pentylentetrazole-induced seizures in mice: possible role of adenosine A1 receptors. *Neuropsychopharmacology* **2007**, *32*, 412-416.
199. Florio, C.; Prezioso, A.; Papaioannou, A.; Vertua, R. Adenosine A1 receptors modulate anxiety in CD1 mice. *Psychopharmacology (Berl)* **1998**, *136*, 311-319.
200. Jain, N.; Kemp, N.; Adeyemo, O.; Buchanan, P.; Stone, T.W. Anxiolytic activity of adenosine receptor activation in mice. *Br. J. Pharmacol.* **1995**, *116*, 2127-2133.
201. Prediger, R.D.; Batista, L.C.; Takahashi, R.N. Adenosine A1 receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice. *Eur. J. Pharmacol.* **2004**, *499*, 147-154.
202. Prediger, R.D.; da Silva, G.E.; Batista, L.C.; Bittencourt, A.L.; Takahashi, R.N. Activation of adenosine A1 receptors reduces anxiety-like behavior during acute ethanol withdrawal (hangover) in mice. *Neuropsychopharmacology* **2006**, *31*, 2210-2220.
203. File, S.E.; Andrews, N.; al Farhan, M. Anxiogenic responses of rats on withdrawal from chronic ethanol treatment: effects of tianeptine. *Alcohol Alcohol.* **1993**, *28*, 281-286.
204. File, S.E.; Mabbutt, P.S. Effects of tianeptine in animal-models of anxiety and on learning and memory. *Drug Dev. Res.* **1991**, *23*, 47-56.
205. Defrance, R.; Marey, C.; Kamoun, A. Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. *Clin. Neuropharmacol.* **1988**, *11* (Suppl. 2), S74-S82.
206. Wilde, M.I.; Benfield, P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. *Drugs* **1995**, *49*, 411-439.
207. Guelfi, J.D.; Pichot, P.; Dreyfus, J.F. Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. *Neuropsychobiology* **1989**, *22*, 41-48.

208. Onder, E.; Tural, U.; Aker, T. A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. *Eur. Psychiatry* **2006**, *21*, 174-179.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).